NR3C2 and hydrops fetalis: Despite the lower risk of death in HFpEF (regardless of age, gender, and etiology of HF) compared to patients with HFrEF, those with HFpEF still have high absolute mortality, and unfortunately do not benefit from neurohormonal antagonists (i.e. beta blockers, angiontensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), mineralocorticoid receptor antagonists, ARB-neprilysin inhibitors) or intracardiac devices as well as do patients with HFrEF [2, 4, 5, 16].